Market narrative

Read the headlines around the signals.

Move between stock news, official company releases, crypto, and FX without losing the path back to ticker research.

Latest prnewswire.com · 1 day ago

OppFi to Participate in August 2026 Conferences

CHICAGO, Aug. 4, 2026 /PRNewswire/ -- OppFi Inc. (NYSE: OPFI) ("OppFi" or the "Company"), a leading tech-enabled digital finance platform that works with banks to provide financial products and services for everyday Americans, today announced that Chief Executive Officer, Todd Schwartz, and Chief Financial Officer, Pam Johnson, will participate in the following conferences in August 2026: 8 th Annual Needham Virtual Fintech & Digital Transformation Conference Location: VirtualDate: August 13-14, 2026 2026 Seaport Research Partners Annual Summer Investor Conference Location: VirtualDate: August 18-19, 2026 To schedule a meeting with OppFi, please reach out to your Needham or Seaport representatives. About OppFi OppFi (NYSE: OPFI) is a leading tech-enabled digital finance platform that works with banks to provide financial products and services for everyday Americans.

Press releases

More recent coverage

Page 84
FACO accessnewswire.com · 1 day ago

First Acceptance Corporation Reports Operating Results for the Three and Six Months Ended June 30, 2026

Second Quarter Net Income Increases 28% from $7.9 Million to $10.1 Million Company Records 14th Consecutive Profitable Quarter NASHVILLE, TN / ACCESS Newswire / August 4, 2026 / First Acceptance Corporation (OTCQX:FACO) today reported its financial results for the three and six months ended June 30, 2026. A quarterly report can be found at www.otcmarkets.com/stock/FACO/disclosure.

CACC globenewswire.com · 1 day ago

Credit Acceptance Announces Second Quarter 2026 Results

Southfield, Michigan, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Credit A cceptance Corporation (Nasdaq: CACC) (referred to as the “Company”, “Credit Acceptance”, “we”, “our”, or “us”) today announced consolidated net income of $135.9 million, or $12.66 per diluted share, for the three months ended June 30, 2026. Adjusted net income, a non-GAAP financial measure, for the three months ended June 30, 2026 was $130.1 million, or $12.12 per diluted share. The following table summarizes our financial results:

GTBIF globenewswire.com · 1 day ago

Green Thumb Industries Reports Second Quarter 2026 Results

CHICAGO and VANCOUVER, British Columbia, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Green Thumb Industries Inc.  (“Green Thumb” or the “Company”) (CSE: GTII) (OTCQX: GTBIF), a leading national cannabis consumer packaged goods company and owner of  RISE Dispensaries , today reported its financial results for the quarter ended June 30, 2026. Financial results are reported in accordance with U.S. generally accepted accounting principles (“GAAP”), and all currency is in U.S. dollars.

NAGE businesswire.com · 1 day ago

Niagen Bioscience, Inc. Reports Second Quarter 2026 Financial Results

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ:NAGE) today announced operational updates and financial results for the second quarter of 2026. Second Quarter 2026 Financial and Business Highlights Total net sales of $29.8 million, including $24.2 million from Tru Niagen®. Direct to consumer sales on the Company's website grew by 23% year-over-year. Gross margin of 64.8%, reflecting continued strength in business mix. Net income of $1.0 million, with basic and diluted earnings per.

ADMA newsfilecorp.com · 1 day ago

ADMA BIOLOGICS DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages ADMA Biologics, Inc. Investors to Secure Counsel Before Important August 10 Deadline in Securities Class Action First Filed by the Firm - ADMA

New York, New York--(Newsfile Corp. - August 4, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ADMA Biologics, Inc. (NASDAQ: ADMA) between August 9, 2024 and March 25, 2026, both dates inclusive (the "Class Period"), of the important August 10, 2026 lead plaintiff deadline in the securities class action first filed by the Firm. SO WHAT: If you purchased ADMA Biologics securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

PSKY prnewswire.com · 1 day ago

PARAMOUNT REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS

LOS ANGELES and NEW YORK, Aug. 4, 2026 /PRNewswire/ -- Paramount Skydance Corporation (Nasdaq: PSKY) today announced financial results for the second quarter ending June 30, 2026. The company will conduct a conference call with a live audio webcast available on Paramount's Investors homepage at ir.paramount.com beginning at 2:00 p.m.

RIGL prnewswire.com · 1 day ago

Rigel Reports Second Quarter 2026 Financial Results

Second quarter 2026 total revenues of $78.7 million, including net product sales of $67.0 million and contract revenues from collaborations of $11.7 million, and net income of $17.3 million Expanded commercial portfolio with the in-license of VEPPANU™ (vepdegestrant), with U.S. commercial availability expected in mid-August Advanced R289 development program; Phase 1b study in patients with lower-risk MDS remains on track to complete enrollment in the dose expansion portion and select the recommended Phase 2 dose in the second half of 2026 Updated 2026 Outlook: Total revenues of approximately $285 to $295 million, which includes net product sales, excluding VEPPANU, of $255 to $265 million and contract revenues from collaborations of approximately $30 million Conference call and webcast scheduled today at 4:30 p.m. Eastern Time SOUTH SAN FRANCISCO, Calif.

PGEN prnewswire.com · 1 day ago

Precigen Reports Second Quarter 2026 Financial Results Highlighted by Accelerating PAPZIMEOS Revenue Growth

PAPZIMEOS ® net revenue of $53.1 million in the second quarter of 2026, more than double the prior quarter, reflects accelerating commercial momentum and broad US adoption PAPZIMEOS revenue propelled the Company to quarterly profitability Cash, cash equivalents, and investments totaled $38.7 million as of June 30, 2026, which together with proceeds from PAPZIMEOS revenue, is expected to support cash flow break-even by the end of 2026 PAPZIMEOS patient hub enrollment reached well over 500 patients across major centers and community practices, demonstrating expanding reach and ease of administration across treatment settings FDA granted PAPZIMEOS seven-year market exclusivity, providing long-term protection against prospective competition Conference call scheduled for 4:30 PM ET today GERMANTOWN, Md., Aug. 4, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced second quarter 2026 financial results and business updates.

ALGT prnewswire.com · 1 day ago

ALLEGIANT TRAVEL COMPANYSECOND QUARTER 2026 FINANCIAL RESULTS*

Second quarter 2026 GAAP loss per share of $(0.21) (1) Second quarter 2026 adjusted diluted earnings per share of $2.19 (2)(3)(4) , up 78.0 percent year-over-year * Second quarter results include the financial performance of Sun Country only from and after the date the acquisition closed on May 13, 2026 LAS VEGAS., Aug. 4, 2026 /PRNewswire/ -- Allegiant Travel Company (NASDAQ: ALGT) today reported the below financial results for second quarter 2026, as well as comparisons to the prior year.

ATOM prnewswire.com · 1 day ago

Atomera Provides Second Quarter 2026 Results

LOS GATOS, Calif., Aug. 4, 2026 /PRNewswire/ -- ­­ Atomera Incorporated (NASDAQ: ATOM), a semiconductor materials and technology licensing company, today provided a corporate update and announced financial results for the second quarter ended June 30, 2026.

RRR prnewswire.com · 1 day ago

Red Rock Resorts Announces Second Quarter 2026 Results

LAS VEGAS, Aug. 4, 2026 /PRNewswire/ -- Red Rock Resorts, Inc. ("Red Rock Resorts," "we" or the "Company") (NASDAQ: RRR) today reported financial results for the second quarter ended June 30, 2026. Second Quarter Results Consolidated Operations Net revenues were $510.3 million for the second quarter of 2026, a decrease of 3.0%, or $16.0 million, from $526.3 million in the same period of 2025.

WYNN prnewswire.com · 1 day ago

Wynn Resorts, Limited Reports Second Quarter 2026 Results

LAS VEGAS, August 4, 2026 /PRNewswire/ -- Wynn Resorts, Limited (NASDAQ: WYNN) ("Wynn Resorts" or the "Company") today reported financial results for the second quarter ended June 30, 2026. Operating revenues were $1.86 billion for the second quarter of 2026, an increase of $119.1 million from $1.74 billion for the second quarter of 2025.

RYTM globenewswire.com · 1 day ago

Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences

BOSTON, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that David Meeker, M.D., Chairman, President and Chief Executive Officer, and Hunter Smith, Chief Financial Officer, will participate in fireside chats at three upcoming conferences.

MIST globenewswire.com · 1 day ago

Milestone Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 12, 2026

MONTREAL and CHARLOTTE, N.C., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it will report financial results for the second quarter ended June 30, 2026, on Wednesday, August 12, and provide a business update before the market open.

DRS globenewswire.com · 1 day ago

Leonardo DRS Signs Agreement for New Brookfield, Connecticut, Facility to Support Growth of Naval Power Systems Business

ARLINGTON, Va., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Leonardo DRS, Inc. (Nasdaq: DRS) announced today that it has signed an agreement for a new facility in Brookfield, Connecticut, that will expand and consolidate operations for its Naval Power Systems business, strengthening increased throughput and support for critical U.S. Navy programs and positioning the company for future growth across the evolving nuclear energy landscape.

PCRX globenewswire.com · 1 day ago

Pacira BioSciences Reports Second Quarter 2026 Financial Results

-- Continued execution of 5x30 strategy marked by solid revenue growth, durable cashflows, advancing pipeline, and high-caliber commercial partnerships -- -- Delivered second quarter total revenue of $192.4 million, representing 6 percent year-over-year growth -- -- Conference call today at 4:30 p.m. ET -- BRISBANE, Calif.

← Newer
Older →